Literature DB >> 2295049

Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer. An immunohistochemical study.

J A Henry1, A L McCarthy, B Angus, B R Westley, F E May, S Nicholson, J Cairns, A L Harris, C H Horne.   

Abstract

Expression of the estrogen-regulated lysosomal protease, cathepsin D, was studied in a series of 94 breast cancers using an immunohistochemical technique. Granular staining of tumor cell cytoplasm was detected in 62 cases. Positive staining was associated with a significant increase in overall time to relapse and when survival was analyzed in terms of intensity of cathepsin D staining there was a significant trend for both increased time to relapse and increased length of survival. The presence of estrogen receptor was associated with positive cathepsin D immunostaining, and in the subgroup of estrogen receptor-positive tumors cathepsin D staining was associated with significantly prolonged survival; this was not the case for estrogen receptor-negative tumors. Positive cathepsin D immunostaining was associated with significant prognostic advantage in patients with confirmed lymph node metastasis but not in node-negative patients. It is suggested that cathepsin D expression reflects the functional integrity of the estrogen response pathway. Cathepsin D may prove a clinically useful adjunct to assessment of estrogen receptor status.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2295049     DOI: 10.1002/1097-0142(19900115)65:2<265::aid-cncr2820650214>3.0.co;2-1

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  38 in total

1.  Clinical and Histological Prognostic Factors in Axillary Node-Negative BreastCancer: Univariate and Multivariate Analysis with Relation to 5-Year Recurrence.

Authors: 
Journal:  Breast Cancer       Date:  1995-04-30       Impact factor: 4.239

2.  Cathepsin D detected by automated and quantitative immunohistochemistry in breast carcinomas: correlation with overall and disease free survival.

Authors:  C Charpin; S Garcia; C Bouvier; F Martini; M Lavaut; C Allasia; P Bonnier; L Andrac
Journal:  J Clin Pathol       Date:  1997-07       Impact factor: 3.411

Review 3.  The role of proteolytic enzymes in cancer invasion and metastasis.

Authors:  M J Duffy
Journal:  Clin Exp Metastasis       Date:  1992-05       Impact factor: 5.150

4.  Association of ICAM-1, VCAM-1, CYCLIN D1 and Cathepsin D with Clinicopathological Parameters in Breast Carcinoma; an Immunohistochemical Study.

Authors:  Özgür Külahcı; H Hasan Esen; Elife Asut; Salim Güngör
Journal:  J Breast Health       Date:  2017-01-01

5.  Immunohistochemical profile of invasive lobular carcinoma of the breast: predominantly vimentin and p53 protein negative, cathepsin D and oestrogen receptor positive.

Authors:  W Domagala; M Markiewski; R Kubiak; J Bartkowiak; M Osborn
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

6.  Quantitative immunohistochemical determination of cathepsin-D and its relation with other variables.

Authors:  S Veneroni; M G Daidone; G Di Fronzo; V Cappelletti; D Amadori; A Riccobon; A Paradiso; M Correale; R Silvestrini
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

7.  Cathepsin-D expression in cervical carcinoma and its prognostic significance.

Authors:  K M Mitchell; R J Hale; C H Buckley; H Fox; D Smith
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

8.  Cathepsin D in invasive ductal NOS breast carcinoma as defined by immunohistochemistry. No correlation with survival at 5 years.

Authors:  W Domagala; G Striker; A Szadowska; A Dukowicz; K Weber; M Osborn
Journal:  Am J Pathol       Date:  1992-11       Impact factor: 4.307

9.  Comparative biochemical and immunohistochemical studies on the cathepsin D content of human breast cancer.

Authors:  W Remmele; J Sauer-Manthey
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

Review 10.  Evaluation of cathepsin D as a prognostic factor in breast cancer.

Authors:  P M Ravdin
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.